Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-018362
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-08 20:42:28
Reporting Period:
2018-03-06
Accepted Time:
2018-03-08 20:42:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921299 Fibrogen Inc FGEN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1623238 B Thomas Neff C/o Fibrogen, Inc.
409 Illinois St.
San Francisco CA 94158
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-03-06 16,199 $53.55 2,907,425 No 4 F Direct
Common Stock Acquisiton 2018-03-07 10,265 $2.35 2,917,690 No 4 M Direct
Common Stock Disposition 2018-03-07 8,802 $52.58 2,908,888 No 4 S Direct
Common Stock Disposition 2018-03-07 7,800 $53.26 2,901,088 No 4 S Direct
Common Stock Disposition 2018-03-07 2,298 $54.14 2,898,790 No 4 S Direct
Common Stock Disposition 2018-03-07 700 $52.82 121,634 No 4 S Indirect By Family Partnership
Common Stock Disposition 2018-03-07 218 $53.91 121,416 No 4 S Indirect By Family Partnership
Common Stock Acquisiton 2018-03-08 7,005 $2.35 2,905,795 No 4 M Direct
Common Stock Acquisiton 2018-03-08 3,314 $3.60 2,909,109 No 4 M Direct
Common Stock Disposition 2018-03-08 6,400 $52.74 2,902,709 No 4 S Direct
Common Stock Disposition 2018-03-08 11,800 $53.44 2,890,909 No 4 S Direct
Common Stock Disposition 2018-03-08 700 $54.09 2,890,209 No 4 S Direct
Common Stock Disposition 2018-03-08 300 $52.55 121,116 No 4 S Indirect By Family Partnership
Common Stock Disposition 2018-03-08 618 $53.59 120,498 No 4 S Indirect By Family Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
No 4 S Indirect By Family Partnership
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
No 4 S Indirect By Family Partnership
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-03-07 10,265 $0.00 10,265 $2.35
Common Stock Stock Option (Right to Buy) Disposition 2018-03-08 7,005 $0.00 7,005 $2.35
Common Stock Stock Option (Right to Buy) Disposition 2018-03-08 3,314 $0.00 3,314 $3.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,005 2018-03-12 No 4 M Direct
0 2018-03-12 No 4 M Direct
472,145 2019-03-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 19,500 Indirect By Spouse
Common Stock 60,946 Indirect See footnote
Footnotes
  1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
  2. Shares sold pursuant to a 10b5-1 plan.
  3. The shares were sold at prices ranging from $52.00 to $52.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. The shares were sold at prices ranging from $53.00 to $53.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. The shares were sold at prices ranging from $54.00 to $54.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. The shares were sold at prices ranging from $52.30 to $53.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  7. The shares were sold at prices ranging from $53.55 to $54.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  8. The shares were sold at prices ranging from $52.05 to $53.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  9. The shares were sold at prices ranging from $53.05 to $53.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  10. The shares were sold at prices ranging from $54.00 to $54.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  11. The shares were sold at prices ranging from $52.05 to $52.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  12. The shares were sold at prices ranging from $53.20 to $54.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  13. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
  14. Fully vested.